Recombinant Human CXCL5/ENA-74 Protein
R&D Systems, part of Bio-Techne | Catalog # 651-NA
Key Product Details
- R&D Systems E. coli-derived Recombinant Human CXCL5/ENA-74 Protein (651-NA)
- Quality control testing to verify active proteins with lot specific assays by in-house scientists
- All R&D Systems proteins are covered with a 100% guarantee
Product Specifications
Source
E. coli-derived human CXCL5/ENA-74 protein
Ala41-Asn114
Ala41-Asn114
Purity
>97%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<0.01 EU per 1 μg of the protein by the LAL method.
N-terminal Sequence Analysis
Ala41
Predicted Molecular Mass
8.0 kDa
Activity
Measured by its ability to induce myeloperoxidase release from cytochalasin B-treated human neutrophils. Schröder, J.M. et al. (1987) J. Immunol. 139:3474.
The ED50 for this effect is 0.5-1.5 µg/mL.
Measured by its ability to chemoattract BaF3 mouse pro-B cells transfected with human CXCR2.
The ED50 for this effect is 0.3-1.5 ng/mL.
The ED50 for this effect is 0.5-1.5 µg/mL.
Measured by its ability to chemoattract BaF3 mouse pro-B cells transfected with human CXCR2.
The ED50 for this effect is 0.3-1.5 ng/mL.
Reviewed Applications
Read 1 review rated 5 using 651-NA in the following applications:
Formulation, Preparation and Storage
Carrier Free
What does CF mean?CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
What formulation is right for me?In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
Carrier: 651-NA
| Formulation | Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA with BSA as a carrier protein. |
| Reconstitution | Reconstitute at 25 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Carrier Free: 651-NA/CF
| Formulation | Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA. |
| Reconstitution | Reconstitute at 100 μg/mL in sterile PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: CXCL5/ENA-74
35%-51% with CXCL1/GRO alpha, CXCL2/GRO beta, CXCL3/GRO gamma, CXCL7/NAP-2, and CXCL8/IL-8. Inflammatory stimulation up-regulates CXCL5 production in multiple hematopoietic cell types, fibroblasts, endothelial cells, and vascular smooth muscle cells. In vivo, CXCL5 is elevated at sites of inflammation and pulmonary fibrosis where it promotes neutrophil infiltration and activation as well as angiogenesis (3-6). Its up-regulation contributes to increased vascularization, tumor growth, and metastasis in many cancers (6-9). Full length CXCL5 (78 aa) is trimmed at the N-terminal end by cathepsin G and chymotrypsin to ENA-74 (74 aa) and ENA-70 (70 aa), with the shortened forms showing increased potency relative to full length CXCL5 (10, 11). CXCL5 exerts its effects primarily through interactions with CXCR2 (6, 12). It also binds DARC, a decoy chemokine receptor which can limit CXCR2-mediated responses (13, 14).
References
- Strieter, R.M. et al. (2005) Cytokine Growth Factor Rev. 16:593.
- Balestrieri, M.L. et al. (2008) Cardiovasc. Res. 78:250.
- Walz, A. et al. (1991) J. Exp. Med. 174:1355.
- Strieter, R.M. et al. (1992) Immunol. Invest. 21:549.
- Koch, A.E. et al. (1994) J. Clin. Invest. 94:1012.
- Begley, L.A. et al. (2008) Neoplasia 10:244.
- Vandercappellen, J. et al. (2008) Cancer Lett. 267:226.
- Arenberg, D.A. et al. (1998) J. Clin. Invest. 102:465.
- Miyazaki, H. et al. (2006) Cancer Res. 66:4279.
- Wuyts, A. et al. (1999) Eur. J. Biochem. 260:421.
- Nufer, O. et al. (1999) Biochemistry 38:636.
- Ahuja, S.K. and P.M. Murphy (1996) J. Biol. Chem. 271:20545.
- Kashiwazaki, M. et al. (2003) Int. Immunol. 15:1219.
- Horton, L.W. et al. (2007) Cancer Res. 67:9791.
Alternate Names
ENA-74, ENA74
Entrez Gene IDs
6374 (Human)
Gene Symbol
CXCL5
UniProt
Additional CXCL5/ENA-74 Products
Product Documents for Recombinant Human CXCL5/ENA-74 Protein
Product Specific Notices for Recombinant Human CXCL5/ENA-74 Protein
For research use only
Loading...
Loading...
Loading...